Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADIP: IPX203 vs immediate-release levodopa in advanced Parkinson’s disease with motor fluctuations
2025-521772-57-00Phase 3Authorised
- Sponsor
- Zambon
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of levodopa + carbidopa in Parkinson's disease (PD) (2 arms), sponsored by Zambon. Primary endpoint: Change in good ON time at Week 12 vs baseline. Planned start Oct 2025; status: authorised.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-521772-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521772-57-00.